Stuff Karin, Kainz Elena, Kahl Ursula, Pinnschmidt Hans, Beck Stefanie, von Breunig Franziska, Nitzschke Rainer, Funcke Sandra, Zöllner Christian, Fischer Marlene
Department of Anaesthesiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Perioper Med (Lond). 2022 May 19;11(1):18. doi: 10.1186/s13741-022-00253-4.
Sedative premedication with benzodiazepines has been linked with prolonged recovery and inadequate emergence during the immediate postoperative period. We aimed to analyze the association between postanesthesia care unit (PACU) delirium and sedative premedication with oral midazolam.
We performed a secondary analysis of prospectively collected data before (midazolam cohort) and after (non-midazolam cohort) implementation of a restrictive strategy for oral premedication with midazolam. From March 2015 until July 2018, we included patients 60 years and older, who underwent elective radical prostatectomy for prostate cancer. Exclusion criteria were contraindications to premedication with midazolam, preoperative anxiety, and a history of neurological disorders. Patients, who were scheduled for postoperative admission to the intensive care unit, were excluded. Between 2015 and 2016, patients received 7.5 mg oral midazolam preoperatively (midazolam cohort). Patients included between 2017 and 2018 did not receive any sedative medication preoperatively (non-midazolam cohort). The primary endpoint was the incidence of PACU delirium.
PACU delirium rates were 49% in the midazolam cohort (n = 214) and 33% in the non-midazolam cohort (n = 218). This difference was not statistically significant on multivariable logistic regression analysis (OR 0.847 [95% CI 0.164; 4.367]; P = 0.842). Age (OR 1.102 [95% CI 1.050; 1.156]; P < 0.001), the cumulative dose of sufentanil (OR 1.014 [95% CI 1.005; 1.024]; P = 0.005), and propofol-sufentanil for anesthesia maintenance (OR 2.805 [95% CI 1.497; 5.256]; P = 0.001) were significantly associated with PACU delirium.
Midazolam for sedative premedication was not significantly associated with PACU delirium. The reduction in the incidence of PACU delirium throughout the study period may be attributable to improvements in perioperative management other than a more restrictive preoperative benzodiazepine administration.
苯二氮䓬类药物的镇静术前用药与术后即刻恢复时间延长和苏醒不充分有关。我们旨在分析麻醉后监护病房(PACU)谵妄与口服咪达唑仑镇静术前用药之间的关联。
我们对前瞻性收集的数据进行了二次分析,这些数据来自实施咪达唑仑口服术前用药限制策略之前(咪达唑仑组)和之后(非咪达唑仑组)。从2015年3月至2018年7月,我们纳入了60岁及以上接受前列腺癌择期根治性前列腺切除术的患者。排除标准为咪达唑仑术前用药的禁忌症、术前焦虑和神经系统疾病史。计划术后入住重症监护病房的患者被排除。2015年至2016年期间,患者术前接受7.5mg口服咪达唑仑(咪达唑仑组)。2017年至2018年期间纳入的患者术前未接受任何镇静药物(非咪达唑仑组)。主要终点是PACU谵妄的发生率。
咪达唑仑组(n = 214)的PACU谵妄发生率为49%,非咪达唑仑组(n = 218)为33%。在多变量逻辑回归分析中,这种差异无统计学意义(OR 0.847 [95% CI 0.164; 4.367]; P = 0.842)。年龄(OR 1.102 [95% CI 1.050; 1.156]; P < 0.001)、舒芬太尼累积剂量(OR 1.014 [95% CI 1.005; 1.024]; P = 0.005)以及用于麻醉维持的丙泊酚-舒芬太尼(OR 2.805 [95% CI 1.497; 5.256]; P = 0.001)与PACU谵妄显著相关。
用于镇静术前用药的咪达唑仑与PACU谵妄无显著关联。在整个研究期间,PACU谵妄发生率的降低可能归因于围手术期管理的改善,而非术前苯二氮䓬类药物给药限制的加强。